PROGNOSTIC VALUE OF COMPUTED TOMOGRAPHY PULMONARY METASTASIS SIZE AND THYROGLOBULIN CONCENTRATION IN PATIENTS WITH LUNG METASTASES FROM DIFFERENTIATED THYROID CANCER

Quốc Khánh Lê 1, , Văn Đàn Ngô2, Bá Khoa Trần 1, Huy Thông Mai 1, Thị Phương Nguyễn 1, Thanh Hải Nguyễn 3, Ngọc Hà Lê 1
1 Bệnh viện Trung ương Quân đội 108
2 Bệnh viện Quân y 103
3 Bệnh viện Đa khoa Quốc tế Vinmec Times City

Main Article Content

Abstract

Background: Thyroglobulin (Tg) levels and pulmonary metastasis size on computed tomography (CT) are routine indicators in the management of differentiated thyroid cancer (DTC) with pulmonary metastases. However, their optimal prognostic cut-offs for mortality in Vietnam remain unclear.


Subjects and Methods: A retrospective and prospective descriptive study was conducted on 165 DTC patients with lung metastases who underwent total thyroidectomy and I-131 therapy at the 108 Military Central Hospital from August 2004 to March 2026. Receiver Operating Characteristic (ROC) curve analysis, Area Under the Curve (AUC), and Youden's index were utilized to identify the optimal cut-offs for predicting mortality.


Results: The ROC curve for pre-treatment stimulated Tg (n=159) yielded an AUC of 0.686; the optimal cut-off was 207 ng/mL with a sensitivity of 88.46% and a specificity of 54.89%. CT lesion size (n=160) demonstrated a better prognostic value with an AUC of 0.799; the optimal cut-off was identified as 5 mm, yielding a sensitivity of 80.77% and a specificity of 74.63%.


Conclusion: CT lung metastasis size shows a good prognostic value (cut-off > 5 mm), whereas Tg levels provide a moderate early warning value (cut-off > 207 ng/mL). Combining these indicators assists clinicians in risk stratification and optimizing treatment protocols.

Article Details

References

1. Haugen, b.R., Et al., 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the american thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid, 2016. 26(1): P. 1-133.
2. Miyauchi, a., Et al., Prognostic impact of serum thyroglobulin doubling-time under thyrotropin suppression in patients with papillary thyroid carcinoma who underwent total thyroidectomy. Thyroid, 2011. 21(7): P. 707-16.
3. Sabra, m.M., Et al., Clinical outcomes and molecular profile of differentiated thyroid cancers with radioiodine-avid distant metastases. J clin endocrinol metab, 2013. 98(5): P. E829-36.
4. Hội, n.V., Et al., Kết quả điều trị ung thư tuyến giáp thể biệt hóa di căn phổi bằng i-131 tại bệnh viện ung bướu nghệ an. 2024(56): P. 31-40.
5. Akatani, n., Et al., Long-term outcomes and prognostic factors of patients with lung metastases from differentiated thyroid cancer after radioiodine therapy in japan. 2023. 70(3): P. 315-322.
6. Wang, r., Et al., Analysis of radioiodine therapy and prognostic factors of differentiated thyroid cancer patients with pulmonary metastasis: an 8-year retrospective study. Medicine (baltimore), 2017. 96(19): P. E6809.
7. Ito, y., Et al., Prognostic factors for recurrence of papillary thyroid carcinoma in the lymph nodes, lung, and bone: analysis of 5,768 patients with average 10-year follow-up. 2012. 36(6): P. 1274-1278.